Covıd-19, Astrazeneca, Life & Health, Science

Covıd-19, Astrazeneca

AstraZeneca antibody cocktail fails to prevent COVID-19 symptoms in large trial

The study assesses whether AZD7442 could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms

6/15/2021 10:38:00 PM

The study assesses whether the therapy AZD7442 could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

The study assesses whether AZD7442 could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms

ReutersAstraZeneca said on Tuesday, June 15, a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

DOH: Still no community transmission of COVID-19 Delta variant detected in PH After Olympic gold, Hidilyn's next goal is a diploma ‘The West Philippine Sea is ours,’ says Hidilyn Diaz

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant – meaning it might have been due to chance and not the therapy.

The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants. headtopics.com

"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product's fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

Targeted alternativesAZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.Similar therapies developed by rivals Regeneron and Eli Lilly have been approved by US regulators for treating unhospitalized COVID patients.

European regulators have also authorized Regeneron's therapy and are reviewing those developed by partners GlaxoSmithKline and Vir Biotechnology as well as by Lilly and Celltrion.Regeneron is also seeking US authorization for its therapy as a preventative treatment. headtopics.com

Metro Manila still under week-long GCQ, to shift to ECQ starting August 6 CHR cries ‘discrimination’ for the unvaccinated barred from going out Tito, Vic at Joey, nag-reunion sa 'Eat Bulaga'

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.AstraZeneca also said on Tuesday it was in talks with the US government on"next steps" regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.The full results will be submitted for publication in a peer-reviewed medical journal, the company said. – Read more: Rappler »

Gordon says he met with VP Robredo for partnership in 2022 polls

Senator Richard Gordon said Wednesday he had met with Vice President Leni Robredo for a partnership in next year's elections.

Novavax: Large study finds Covid-19 shot about 90% effectiveVACCINE maker Novavax said Monday, June 14, its shot was highly effective against Covid-19 and also protected against variants in a large, late-stage...

Organ transplant patients may benefit from third COVID-19 vaccine dose to boost antibodies, study suggestsA third dose of coronavirus vaccine could help boost antibody levels among some organ transplant recipients who have not had robust responses to the standard vaccination schedules, a new study suggests.

Population protection vs COVID-19 achieved by December, Palace assures😂😂😂😂

How satellites help fight COVID-19 in PHOr is this a human monitoring same as with china human monitoring... Whatever happened to privacy... I still want my privacy!

Duterte orders Cebu to follow protocols from COVID-19 task forcePresident Rodrigo Duterte has directed Cebu province to follow protocols from the inter-agency task force leading the Philippines' COVID-19 response, Malacañang said on Monday. Hahaha...bobo lang talaga Cebu? Mahigit na isang taong ang pandemya. Tapos pagsasabihan pa ni Kanor na sumunod? Kailangan pa bang i memorize yan? Pag bobo and lider nabobo lahat. Hahaha

57 new COVID-19 deaths bring PH’s total to 22,845MANILA, Philippines — The Department of Health (DOH) reported Monday that 57 more COVID-19 patients died of the severe respiratory disease, bringing the country&039;s death toll to